drugset / Trial / NCT00157248

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

NCT00157248

Phase 2 Terminated 361 enrolled Boehringer Ingelheim
Non-randomizedOpen-labelPrevention

Summary

To determine the long term safety and efficacy of BIBR 1048 in patients with chronic atrial fibrilla tion, with or without concomitant chronic treatment with acetylsalicylic acid (ASA).

Timeline

Start
2003-12
Primary completion
2009-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg
Subject Dabigatran etexilate Unknown 300 mg